Mikhail Blagosklonny is very concerned about aging and related illnesses. He studied at the First Pavlov state medical university in St Petersburg. While at the institution, he earned an M.D in internal medicine. Mikhail Blagoskolonny boost of a PhD in cardiology and experimental medicine. After his graduation, he was employed by New York Medical College as an associate professor of medicine in its Valhalla College. He is a professor of Oncology at the Roswell cancer institute.
Mikhail Blagosklonny is very committed in cancer and aging related complications and conditions. Aging has been perceived as a functional decline, which is brought by the accumulation of the random molecular damage. People also believed that aging couldn’t be prevented. Breaking this misconception, the hyperfunction theory has described aging as a continuation of growth powered by signalling pathways that include Target of Rapamycin (TOR). TheTOR- centric model works behind the idea that rapamycin is very essential in treating aging and related illnesses and that if given in the right doses and sequence can boost and extend healthy life span. This theory has received its fair share of ridicule nonetheless.
The study that Evirolimus (a rapamycin analog) boosts immunity in aging human beings made headlines. This was seen as a turning point in research. In the year 2006, rapamycin was approved as fit for clinical use. It was seen as the most important anti- aging drug invented to slow down aging and aging related illnesses.
Mikhail Blagosklonny has a vast knowledge and experience, which he has gained from his different workstations. He has keen interest in researching areas that include Bio gerontology, anti-aging drugs and cancer. He is the editor-in-chief of the Oncotarget journal and the cell cycle, which are very informative and reliable. Still on that note, he is the associate editor of cancer biology and therapy. He is also part of the editorial board at the cell death and differention board. Mikhail Blagosklonny came up with a proposal regarding the use of rapamycin a drug used to treat cancer. He thought that it could be used for other purposes apart from treating cancer. Mikhail Blagosklonny research fields spins from cellular biology, molecular biology to clinical investigations. He is seen as a crusader for rapamycin.
Mikhail Blagosklonny has authored the aging hyperfunction theory. He is also actively involved in writings especially those to do with cell cyclotherapy and chemotherapeutic engineering. He strongly believes that aging and cancer can be comfortably controlled. He has over 300 articles that are published under his name as well as articles and reviews. He points out his unrivalled love for humankind as his driving force and the idea of a disease free community. Visit ResearchGate to know more about Mikhail’s latest work.